Overview

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Status:
Recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborator:
Servier
Treatments:
Rituximab